-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Medical Rubik's Cube info
On April 9, the indications for the first-line treatment of Epidermal Growth Factor Receptor (EGFR) sensitive mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) with Ametinib tablets by Hausen Pharmaceuticals was proposed by CDE as a breakthrough therapy.
Ametinib mesylate (Amelo) is an oral, effective and highly selective third-generation EGFR-TKI developed by Hausen.
Ametinib tablets have been included in the 2020 medical insurance catalogue through negotiation on December 28 last year (a price reduction of 64%, the negotiated price is 176 yuan / tablet, that is, 3520 yuan per box).
In February this year, Hausen announced that the first-line treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer phase III study of Ametinib reached the primary endpoint.
AstraZeneca Osimertinib tablets have been approved by the NMPA for the first-line treatment of EGFR mutation-positive NSCLC indications and have been included in the new version of the medical insurance catalog.
